DuoRich Sustained Release Tablets 10/500 mg
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
MFDS item code 202204058 · Approved 2022.11.10
Improves glycemic control in adults with type 2 diabetes mellitus
This medication assists adults with type 2 diabetes in controlling blood glucose levels through dietary and exercise therapy, by administering dapagliflozin and metformin together. In particular, for patients with cardiovascular disease or risk factors among those whose blood sugar is not adequately controlled, it is important to refer to specialist information regarding the impact of dapagliflozin on cardiovascular event occurrence. This medication aids in diabetes management by improving blood sugar control.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and in whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce the gastrointestinal adverse effects of metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switched from other antihyperglycemic agents. Because any change may cause changes in glycemic control, all changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication is used for the treatment of diabetes, and one of its active ingredients, metformin hydrochloride, is excreted by the kidneys, so it should not be administered to patients with impaired kidney function. This medication can very rarely cause a serious condition known as lactic acidosis, which is characterized by increased levels of lactic acid in the blood and increased acidity, potentially fatal without appropriate treatment. Additionally, caution is required when taken with insulin or sulfonylureas as hypoglycemia may occur. Patients with moderate or severe renal impairment, dehydration, severe infections, cardiovascular problems, or acute diseases such as acute myocardial infarction should not be administered this medication. Before procedures that use iodinated radiocontrast agents, this medication should be stopped at least 48 hours prior and should not be resumed until renal function is confirmed as normal after the procedure. Prior to surgery, except for minor surgeries with no restrictions on food and fluid intake, this medication should be temporarily stopped 48 hours prior to surgery, and resumed only after normal renal function is confirmed post-surgery. It is not recommended to use this medication in pregnant or breastfeeding women. In elderly patients, because renal function deterioration is common, dose adjustments may be necessary, and regular monitoring of renal function is advised. During treatment with this medication, there may be a risk of dehydration or low blood pressure, so careful monitoring of fluid status and blood pressure is required, particularly if diuretics are being taken concurrently. This medication may increase the risk of genital and urinary tract infections, so if related symptoms develop, prompt consultation with healthcare personnel is necessary. Vitamin B12 levels may decrease, so long-term users should regularly check their vitamin B12 levels. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided during treatment. This medication may induce hypoglycemic symptoms, so caution is needed regarding hypoglycemic symptoms when combined with blood sugar-lowering agents, and adjustments to the doses of these agents may be necessary. In the event of an overdose, contact healthcare personnel immediately for appropriate treatment; the component metformin can be removed through dialysis, which may assist in cases of acute toxicity. During treatment, caution should be exercised while driving or operating machinery due to the risk of dizziness. Finally, this medication should be kept out of the reach of children and stored in its original container to maintain its quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to keep storage temperatures between 1 to 30 degrees Celsius at room temperature. Storing it this way will help maintain the medication's effectiveness for a longer period.
Pink, double convex, egg-shaped film-coated tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.